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Abstract
Background: Human papillomavirus (HPV) has been confirmed as the primary etiological factor
that transforms cervical epithelia into cancer. The presence of HPV in oral cancers suggests that
HPV may play a similar role in transforming the oral epithelia. A high degree of variability in the
prevalence of HPV in oral cancers has been found, however, raising questions regarding its role in
the transformation and development of oral cancers. The goal of this study was to test our
hypothesis that high-risk HPV strains HPV16 and HPV18 will alter the phenotype of transformed
oral squamous cell carcinoma cell lines, CAL27, SCC-15 and SCC-25 in vitro.
Results: CAL27 cells transfected with HPV18, HPV16, as well as HPV16/18 co-transfectants,
demonstrated significant increases in proliferation, adhesion and cell spreading compared with non-
transfected controls. These observed differences were correlated with a small level of increased
cell survival. SCC-15 cells, however, displayed a differential response to HPV transfection, with only
HPV18-transfectants demonstrated changes to proliferation. Interestingly, SCC-25 cells displayed
a more complex response, with HPV16-induced increases in cell proliferation, viability and cell
spreading, while HPV18- and 16/18-transfectants exhibited reduced adhesion and proliferation.
Conclusion: Determining the potential of specific high-risk HPV strains to alter phenotypic
behaviors of already transformed oral carcinomas is a critical step in providing more accurate
prognosis and treatment options for oral cancer patients. The identification of differential
responses to specific HPV strains among oral cancers suggests a more significant, complex and
multifactorial role of HPV, not only in transforming, but also in modulating, the phenotype and
treatment responsiveness of precancerous and cancerous oral lesions. This study provides some
of the first evidence to help identify the important molecular markers for pathways that could be
used to determine the most effective and appropriate treatment plans for oral cancer patients with
concomitant oral HPV infections.
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Background
Human papillomavirus (HPV) has been confirmed as the
primary etiological factor that transforms cervical epithe-
lia into cancer [1]. Certain HPV types are detected in vir-
tually all invasive cervical cancer biopsies and have thus
been designated as oncogenic or high-risk HPV [2,3].
According to epidemiological case-control studies [4], 15
high-risk HPV types have been acknowledged (types 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82),
while 3 types have been designated as probable high-risk
(types 26, 53, and 66) and 12 types have been classified as
low-risk.
Of these high-risk HPV types, HPV16 is the most common
strain present in biopsies from women with cervical squa-
mous cell carcinoma (SCC) and it is also the most com-
mon strain of high-risk HPV from biopsies of head and
neck SCC (HNSCC) [3,5,6]. HPV18 is the second most
commonly found high-risk HPV strain in both invasive
cervical cancer [7] and HNSCC [3]. Other common high-
risk cervical cancer HPV strains are rarely, or never,
detected in oral SCC biopsies [3,8].
Infection of cervical SCC and HNSCC with high-risk HPV
has thus been well documented. Co-infection of these
cancers with more than one high-risk HPV type has also
been documented, but it is not found as frequently as
infections with single high-risk HPV strains [3,7]. When
co-infected HNSCC specimens are identified, however,
they are most often co-infected with HPV16 [3]. Co-infec-
tion of HNSCC with HPV16 and HPV18 has been docu-
mented in a relatively small proportion of samples from
numerous studies [3,9-12].
Recent studies have provided further evidence that HPV is
an independent risk factor for oral SCC, determining that
HPV is found in three times as many precancerous oral
mucosa, and almost five times as many oral cancers, com-
pared with normal oral mucosa [3,5,12-16]. Despite the
increased risk associated with these HPV infections, the
comparatively low incidence of HPV16 and HPV18 in oral
SCC, combined with an even lower prevalence of HPV in
premalignant lesions, suggests that while these high risk
HPV strains may induce transformation in some subset of
oral cancers, they may infect and subsequently act to mod-
ulate phenotypes in established oral SCCs (OSCC) [8].
Much of the literature related to HPV infection and oral
cancers involves retrospective analyses of tumor biopsies
and epidemiologic studies. While these and other studies
have informed our understanding of the roles of HPV in
oral cancer, they have not adequately addressed the appar-
ent contradictory evidence that HPV infection may not be
causally related to the formation of all, or even most, oral
carcinomas. This seemingly contradictory evidence may
be explained by the inability of varied methods, such as
PCR and other detection techniques, to distinguish
between HPV infections causally related to cancer devel-
opment and those that are concomitant, non-causal HPV
infections [17,18]. By examining the effects of HPV on
transformed OSCC in vitro, we may begin to elucidate and
understand the etiologic factors that are necessary and suf-
ficient to transform the oral mucosa and the factors that
may promote proliferative potential in already trans-
formed OSCC.
The pathway of HPV-induced transformation is well
established in cervical SCC, with transformation attribut-
able to the HPV Early (E) genes which code for proteins
that, in addition to promoting viral replication, are capa-
ble of binding and inactivating transcription factors with
tumor suppressor function, such as p53 and Rb, regulators
of cell-cycle checkpoints at the G1 phase [19-21]. The
actions of high-risk HPV gene products play a similar role
in the carcinogenesis and tumor progression in oral can-
cer. [22].
Although some studies have demonstrated the transfor-
mation of human foreskin and cervical keratinocytes in
vitro using HPV16 [23,24], until recently, the role of HPV
in already transformed OSCC had not been investigated.
We recently determined that the OSCC cell line, CAL27,
transfected with HPV16, exhibited significantly increased
proliferation, when compared with non-transfected con-
trols [25]. This increased proliferation was observed even
in the absence of serum, and the effects were specific to
proliferation, adhesion, and morphology, but not to cell
viability.
Based upon our previous studies and the mounting evi-
dence of the possible role of HPV in modulating oral can-
cer phenotypes, we sought to determine if the observed
effects of HPV16 on CAL27 can be generalized to other
high-risk HPV strains and oral cancer cell lines. To this
end, we examined the effects of the two strains of high-risk
HPV most commonly associated with oral cancer, HPV16
and HPV18, both alone and in combination, on the pro-
liferative phenotype of multiple OSCC cell lines in vitro.
Based upon our previous findings that HPV16 induced
increased proliferation [25], we hypothesized that infec-
tion with high risk HPV18 would result in similar pheno-
typic alterations in proliferation, viability, and
morphology of three oral cancer cell lines, CAL27, SCC-
15, and SCC-25. We further hypothesized that co-infec-
tion with HPV16 and HPV18 would also yield phenotypic
changes similar to those observed for CAL27 infected with
HPV16.
Our results provide one of the first demonstrations that
the two high-risk HPV strains most commonly associated
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with oral SCC, HPV16 and HPV18, significantly affect the
proliferative potential of multiple oral cancers in vitro. In
particular, we have determined that among CAL27 cells,
transfection with HPV16 and HPV18, and HPV16/18 co-
transfection, exhibited measurable differences in adhe-
sion, morphology, and proliferation, compared with non-
transfected controls. SCC-15 cells, however, displayed dif-
ferential responses to HPV; HPV18 and co-transfection
increased cell proliferation, while no significant changes
to viability or adhesion were observed. Moreover, SCC-25
cells also displayed a differential response to HPV strains.
Specifically, HPV16 induced a significant increase in pro-
liferation and cell spreading, while HPV18 and HPV16/18
significantly reduced adhesion, proliferation and cell
spreading. Thus, the identification of differential
responses to specific HPV strains among oral cancers may
be the first step to identifying the important molecular
markers and pathways that could be used to develop more
effective and appropriate treatment plans for oral cancer
patients with concomitant oral HPV infections.
Results
Proliferation
Our previous studies of OSCC proliferation of one OSCC
cell line, CAL27, found that CAL27 cells proliferated more
rapidly when plated at higher density, even in the absence
of a serum stimulus. Furthermore, transfection of these
cells with HPV16 further increased the proliferation rate
of CAL27 cells at low density, with this specific effect fur-
ther modulated in the presence of a serum stimulus [25].
Based upon these observations, we hypothesized that
both of the most commonly found high risk oral HPV
strains, HPV16 and HPV18, would similarly modulate the
proliferation of oral cancers in vitro. To test our hypothe-
sis, we expanded our study to include multiple OSCC cell
lines, CAL27, SCC-15, and SCC-25, and also included
both high risk oral HPV types, HPV16 and HPV18.
CAL27
CAL27 cells, CAL27 mock transfectants (mTF), and
CAL27 transfectants with HPV16 (CAL27-HPV16), with
HPV18 (CAL27-HPV18), and co-transfectants (CAL27-
HPV16/18) were plated in media containing fetal bovine
serum (FBS) and their proliferation was measured over
three days in three separate, independent experiments.
Our results demonstrated that the presence of HPV signif-
icantly increased proliferation of CAL27 cells over three
days (n = 96, p < .01): HPV18 (+161%), HPV16 (+172%),
HPV16 and HPV18 co-transfection (+160%) (Fig. 1A).
To reduce the proliferation-stimulating effects of
trypsinizing and plating cells into each experimental
assay, previously observed between day 0 and day 1 in
most assays, we subsequently determined the relative
change in proliferation between day 3 and day 1 (meas-
ured as day 3 minus day 1). Our results from this analysis
revealed that the presence of HPV increased proliferation
of CAL27 cells from a baseline relative-fold increase of
1.325 (CAL27, CAL27 mTF) to an approximate relative
fold-increase of almost 2 for all HPV types tested (HPV18:
Proliferation of CAL27 cells was increased by both HPV18 and HPV16 in vitroFigure 1
Proliferation of CAL27 cells was increased by both 
HPV18 and HPV16 in vitro. HPV-transfected and control 
CAL27 cells were plated in 96-well assay plates with media 
containing 10% fetal bovine serum (FBS) and were allowed to 
proliferate for three days. (A) The addition of HPV16 and 
HPV18, either alone or in combination, was sufficient to stimu-
late the proliferation of CAL27 cells significantly (n = 96, p < 
0.01). (B) Measurements of the relative change in proliferation 
between day 3 and day 1 revealed that the addition of HPV 
stimulated an increase in CAL27 proliferation from 1.3-fold to 
nearly 2.0-fold under each experimental condition. (C) Statisti-
cal tests between non-transfected and transfected cells 
revealed that the HPV-induced increases in proliferation were 
significant, verified using two-tailed t-tests and ANOVA.
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2.0-fold; HPV16: 1.8-fold; HPV16/18: 1.85-fold) (n = 96)
(Fig. 1B).
In addition, we performed two-tailed t-tests to validate
each HPV-induced increase in cellular proliferation in
CAL27 cells. These calculations revealed that each experi-
mental treatment represented a statistically significant
increase in proliferation (HPV18, p < 0.01; HPV16, p <
0.01; HPV16/18, p < 0.01) but were not significantly dif-
ferent from one another (p > 0.05). Because these analyses
involved multiple two-sample t-tests, the results have a
higher probability of Type I error (incorrectly rejecting the
null hypothesis, HO); therefore, ANOVA was performed to
more accurately assess the relationship among groups.
These results indicate a statistically significant difference
between experimental groups, but not within groups (Fig.
1C), providing further validation of the statistical differ-
ences observed with the HPV-transfected CAL27 experi-
mental cells.
SCC-15
To further our understanding of oral cancer behavior, we
expanded our analysis to include the OSCC line, SCC-15.
SCC-15 cells, SCC-15 mock transfectants (mTF), and SCC-
15 transfectants with HPV16 (SCC-15-HPV16), with
HPV18 (SCC-15-HPV18), and co-transfectants (SCC-15-
HPV16/18) were plated in media containing FBS and
their proliferation was measured over three days in three
separate, independent experiments. Our results demon-
strated a differential behavioral response to the HPV
strains tested (n = 96). Specifically, the presence of HPV18
and co-transfection with HPV18 and HPV16 significantly
increased proliferation, increasing it by 55% and 37%,
respectively, over non transfected controls (n = 72, p <
0.01). However, transfection with HPV16 did not produce
a measurable effect on proliferation over the same time
period (n = 48, p > 0.05) (Fig. 2A).
As described above, we determined the relative change in
proliferation between day 3 and day 1 (day 3 minus day
1) for these cells. Our results from SCC-15 cells revealed
that the presence of HPV18 increased proliferation of
SCC-15 cells from a baseline relative-fold increase of
1.897 to a relative fold-increase of more than 3 with
HPV18 (3.099-fold) and co-transfection, HPV18 and
HPV16 (3.236), but not with exposure to HPV16 (1.900),
which was virtually indistinguishable from non-trans-
fected and mock transfected cells (n = 96) (Fig. 2B).
We subsequently performed two-tailed t tests to validate
the differential HPV-specific responses observed in cellu-
lar proliferation of SCC-15 cells. These calculations
revealed a statistically significant increase in proliferation
with HPV18 (n = 48, p < 0.01) and HPV16/18 (n = 48, p
< 0.01). However, SCC-15 response to HPV16 was not sig-
Proliferation of SCC-15 cells was altered by HPV18, alone or in combination with HPV16, but not HPV16 alone, in vitroFigure 2
Proliferation of SCC-15 cells was altered by HPV18, 
alone or in combination with HPV16, but not HPV16 
alone, in vitro. HPV-transfected and control SCC-15 cells 
were plated in 96-well assay plates with media containing 10% 
FBS and were allowed to proliferate for three days. (A) 
HPV18- and HPV16/18 co-transfected SCC-15 cells exhibited 
increased proliferation (n = 120, p < 0.01) although HPV16-
transfectants exhibited no deviation from control or mock-
transfected cells. (B) Relative change in proliferation, measured 
between day 3 and day 1, revealed that proliferation of the 
control and HPV-16 transfectant was approximately 2-fold, 
while the proliferation of HPV18 and co-transfectants 
increased to approximately 3-fold. (C) Two-tailed t-tests and 
ANOVA were used to verify the statistical significance of 
HPV18 and co-transfectants and the lack of significance 
between controls and HPV16-transfected SCC-15 cells.
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nificantly different from non-transfected or mock trans-
fected cells (n = 48, p > 0.05). ANOVA was performed to
more accurately assess the relationship among groups.
These results indicate a statistically significant difference
between experimental groups, but not within groups (Fig.
2C).
SCC-25
We also evaluated the OSCC line, SCC-25, as outlined
previously, and their proliferation was measured over
three days in three separate, independent experiments.
Our results once again demonstrated a differential behav-
ioral response to the HPV strains tested (n = 96). For this
cell line, however, only HPV16 significantly increased
proliferation, 77% over non transfected controls (n = 72,
p < 0.05). Interestingly, neither co-transfection with
HPV16 and HPV18 nor HPV18 alone produced a measur-
able effect on proliferation over the same time period (n
= 72, p > 0.05) (Fig. 3A).
We subsequently determined the relative change in prolif-
eration between day 3 and day 1 and found that the pres-
ence of HPV16 increased proliferation of SCC-25 cells
from a baseline relative-fold increase of 2.047 to a relative
fold-increase of almost 3 (2.768-fold) with HPV16. Trans-
fection with HPV18 resulted in a lower proliferation
(1.142-fold increase, day3 minus day1) compared with
controls, as did co-transfection with HPV16 and HPV18
(1.478-fold increase) (n = 96, p > .05) (Fig. 3B).
We subsequently performed two-tailed t tests to validate
the differential HPV16-specific responses observed in cel-
lular proliferation of SCC-25 cells. These calculations
revealed a statistically significant increase in proliferation
with HPV16 (n = 48, p < 0.05). However, SCC-25
response to HPV18 and HPV16 with HPV18, although
comparatively less than non-transfected cells, was not sig-
nificantly different from these controls (n = 96, p > 0.05).
Furthermore, the results from the one-way ANOVA indi-
cated a statistically significant difference between the
HPV16 experimental group and all other groups (Fig. 3C).
Viability
To evaluate if the HPV-specific changes in proliferation
among these cell lines were related to changes in viability
or cell survival, we determined the percentage of viable
cells from each set of assays we performed (Table 1). Our
results provide evidence that each cell line may display a
characteristic response in viability that is HPV-strain spe-
cific. For example, CAL27 cell viability was measurably
increased by HPV16 (+11%), HPV18 (+22%), and
HPV16/18 (+8%). In addition, SCC-15 cell viability was
only slightly altered by HPV16 (-2%) and HPV18 (-1%),
but was drastically reduced by HPV16/18 co-transfection
(-44%). Finally, SCC-25 cell viability also displayed a dif-
ferential response to HPV16 (+6%), but not to HPV18 (-
1%) or HPV16/18 (+2%).
Adhesion
Based upon the results from cell proliferation and viabil-
ity assays, we sought to determine if these variable
responses might also correlate with measurable altera-
tions in cellular adherence as measured by 30-minute in
vitro adhesion assays (Fig. 4). These analyses revealed that
baseline CAL27 cellular adhesion was also measurably
Proliferation of SCC-25 cells was increased by HPV16 and decreased by HPV18 and co-transfe tion, in vitroFigure 3
Proliferation of SCC-25 cells was increased by HPV16 
and decreased by HPV18 and co-transfection, in vitro. 
HPV-transfected and control SCC-25 cells were plated in 96-
well assay plates with media containing 10% FBS and allowed 
to proliferate for three days. (A) HPV16-transfected cell prolif-
eration was significantly enhanced, while HPV18- and HPV16/
18-cell proliferation was slightly inhibited, compared with con-
trol cells (n = 96, p < 0.05). (B) The relative change in prolifer-
ation as measured between day 3 and day 1 revealed that 
baseline SCC-25 proliferation of 2.-fold was increased to 
approximately 3-fold by HPV16, while HPV18 and HPV16/18 
reduced this rate to approximately 1- and 1.5-fold, respec-
tively. (C) Two-tailed t-tests and ANOVA revealed that only 
HPV16-transfected SCC-25 cells were statistically different 
from controls.
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increased by all HPV treatments; HPV16 (+18%; n = 16, p
= 0.05), HPV18 (+40%; n = 16, p < 0.01), and HPV16/18
(+26%, n = 16, p = 0.01), although the increase in CAL27
adhesion with HPV16 was not statistically significant (Fig.
4A).
SCC-15 adhesion, however, was not significantly
impacted by the presence of HPV, although adhesion was
slightly lower in each HPV-treatment category than in the
non-transfected controls (Fig. 4B); HPV16 (-15%, n = 16,
p = 0.06), HPV18 (-11%, n = 16, p = 0.12) and HPV16/18
(-12%, n = 16, p = 0.17). Interestingly, SCC-25 cell adhe-
sion displayed a differential response to HPV treatment,
increasing with HPV16, although not significantly (+8%,
n = 16, p = .323), but decreasing significantly with HPV18
(-24%, n = 16, p < 0.01) and HPV16/18 (-20%, n = 16, p
< 0.01) (Fig. 4C).
Morphology and cell spreading
Guided by the results of proliferation, viability and adhe-
sion data, we hypothesized that the most striking changes
in cellular morphology and cell spreading would be evi-
dent between the CAL27 non-transfected and HPV-trans-
fectants (Fig. 5). These images demonstrated the increase
in both the absolute number and extent of spreading and
confluence among the HPV16 (Fig. 5B), HPV18 (Fig. 5C),
and HPV16/18 CAL27 (Fig. 5D), compared with CAL27
non-transfected controls (Fig. 5A).
However, the effects of HPV on SCC-15 cells, although
visible, were less prominent (Fig. 6). For example,
although the absolute number of HPV18-transfected SCC-
15 cells was comparatively greater (Fig. 6C), almost all
cells from the HPV16 (Fig. 6B), HPV16/18 (Fig. 6D), and
non-transfected control groups (Fig. 6A) exhibited nearly
uniform spreading.
SCC-25 cells, however, demonstrated a greater differential
response to HPV than either CAL27 or SCC-15 cells (Fig.
7). SCC-25 cell proliferation (Fig. 7A) was conspicuously
increased by the addition of HPV16 to this cell line (Fig.
7B). Moreover, as was also observed in the proliferation
assays. HPV18 (Fig. 7C) and HPV16/18 co-transfectant
(Fig. 7D) proliferation and spreading were noticeably
inhibited in these groups.
Transfection
To determine if the differential effects of HPV on these cell
lines was, in part, due to the efficiency of the transfection,
we measured HPV16, HPV18, and HPV16/18 mRNA from
each cell line prior to, and following, HPV transfection.
RT-PCR from total RNA confirmed the expression of
HPV18 and HPV16 (Fig. 8A) from randomly selected
experiments. Densitometry measurements from multiple
Cell adhesion was altered by HPV18 and co-transfection of HPV16/18 in CAL27 and SCC-25 cellsFigure 4
Cell adhesion was altered by HPV18 and co-transfec-
tion of HPV16/18 in CAL27 and SCC-25 cells. (A) 
CAL27 adhesion was increased by HPV16 (+18%), HPV18 
(+40%) and HPV16/18 (+26%) although only the increases 
among HPV18 and HPV16/18-transfectants were significant (n 
= 32, p < 0.01), as measured by 30-minute in vitro adhesion 
assays. (B) SCC-15 adhesion was slightly reduced by HPV16 (-
15%), HPV18 (-11%) and HPV16/18 (-12%), although these dif-
ferences were not significant (n = 48, p > 0.05). (C) SCC-15 
adhesion was increased slightly by HPV16 (+8%) but was 
decreased significantly by HPV18 (-24%) and HPV16/18 (-20%) 
(n = 32, p < 0.01).
0
0.1
0.2
0.3
0.4
SCC-15 SCC-15-HPV16 SCC-15-HPV18 SCC-15-HPV16/18
R
el
at
iv
e 
ab
so
rb
an
ce
 (
63
0 
n
m
)
0
0.05
0.1
0.15
0.2
CAL27 CAL27-HPV16 CAL27-HPV18 CAL27-HPV16/18
R
el
at
iv
e 
ab
so
rb
an
ce
 (
63
0 
n
m
)
* *
0
0.05
0.1
0.15
0.2
SCC-25 SCC-25-HPV16 SCC-25-HPV18 SCC-25-HPV16/18
R
el
at
iv
e 
ab
so
rb
an
ce
 (
63
0 
n
m
)
* *
A
B
C
Table 1: HPV effects on oral cancer viability in vitro. HPV strains 
induced differential responses among CAL27, SCC-15 and SCC-
25 cell lines. CAL27 viability was increased under all HPV 
experimental conditions, while SCC-15 and SCC-25 exhibited 
more nuanced, differential responses in cell viability to the HPV 
strains tested.
Cell viability no HPV HP16 HPV18 HPV16/18
CAL27 
(% change)
73% 84% (+11%) 95% (+22%) 81% (+8%)
SCC-15 
(%change)
89% 87% (-2%) 88% (-1%) 45% (-44%)
SCC-25 
(% change)
80% 86% (+6%) 79% (-1%) 82% (+2%)
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ethidium bromide (EtBr) band intensities, following rela-
tive endpoint RT-PCR, confirmed transfection efficiency
and revealed comparable HPV expression levels between
an endogenously-expressed HPV strain (GH354 cells) and
HPV-transfected cells from these experiments (Fig. 8B).
Discussion
Infection with high-risk HPV has been implicated in
nearly all cases of cervical intraepithelial neoplasia and
invasive squamous cell carcinomas [23,26,27], and the
presence of HPV DNA in oral leukoplakias and oral malig-
nant lesions suggests that HPV may also function to trans-
form the oral mucosa. However, the comparatively low
presence of HPV in pre-malignant oral lesions, combined
with evidence that HPV is present only in a subset of oral
cancers, implies that HPV infection may instead act to
mediate oral cancer phenotypes in some cases, and possi-
bly contributes to the malignant or transformation proc-
ess rather than being a primary etiologic factor inducing
oral carcinogenesis. We recently reported some of the first
evidence that a high-risk HPV strain, HPV16, induced sig-
nificant phenotypic changes in an already transformed
OSCC line, CAL27 [25] reported significant increases in
proliferation and changes to cell morphology.
Although HPV16 is the most common high-risk HPV
strain in both cervical SCC and OSCC, another high-risk
HPV strain, HPV18, it is also found in OSCC, either alone
or in combination with HPV16. Based upon these obser-
vations, we hypothesized that, HPV16 and HPV18, alone
or in combination, would be sufficient to induce signifi-
cant, measurable alterations to oral cancer phenotypes,
SCC-25 morphology displayed differential responses to HPVFigure 7
SCC-25 morphology displayed differential responses 
to HPV. SCC-25 cells (A) were plated in 96-well plates and 
allowed to proliferation with 10% FBS for three days. (A) 
HPV16-transfected cells exhibited a profound increase in abso-
lute number, confluence and cell spreading, while (B) HPV18- 
and (C) HPV16/18-transfected cells demonstrated visible 
decreases in cell number, spreading and confluence by day 3.
CAL27 morphology was altered by the presence of HPVFigure 5
CAL27 morphology was altered by the presence of 
HPV. CAL27 cells (A) were plated in 96-well plates and 
allowed to proliferation with 10% FBS for three days. (B) 
HPV16-, (C) HPV18- and (D) HPV16/18-transfected cells 
increased in absolute number, confluence, and extent of cell 
spreading than non-transfected or mock-transfected cells (data 
not shown) under these conditions.
SCC-15 morphology was not significantly altered by HPVFigure 6
SCC-15 morphology was not significantly altered by 
HPV. SCC-15 cells (A) were plated in 96-well plates and 
allowed to proliferation with 10% FBS for three days. HPV-
transfected cells (B-D) did not appear to exhibit dramatic and 
significant alterations in cell spreading or confluence by HPV 
treatments.
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particularly to proliferation and cell morphology.
Expanding our study parameters to encompass multiple
OSCC cell lines, including not only CAL27, but also SCC-
15 and SCC-25, we sought to test these hypotheses. Our
results from these expanded studies, however, demon-
strated instead that HPV induced differential responses
between each of these OSCC cell lines, suggesting the
presence of more complex and dynamic relationships
among these variables.
That both of these high-risk, most commonly identified
oral HPV strains, do not elicit equivalent responses in all
cell lines tested is likely because oral cancers, similar to
most other cancers, are not dependent upon a single
receptor or signal transduction pathway for growth, devel-
opment, or progression [28]. These results underscore the
complicated nature of the mechanisms or pathways that
may be common, or ubiquitous, to oral cancers and that
may be potential therapeutic or prevention targets, with-
out significant overlap with pathways necessary for main-
tenance of healthy cells and tissues.
These data combined suggest that understanding the crit-
ical differences that exist between oral and cervical car-
cinogenesis, may provide some insight into the
mechanisms of phenotypic alteration that have been
observed in this study. For example, it has been observed
that while the p53 gene is mutated in most head and neck
tumors, the retinoblastoma (Rb) gene, a critical target of
HPV-mediated transformation of virtually all cervical can-
cers, remains functionally active in many, if not most, oral
cancers [29,30]. Furthermore, inducing an increase in p21
expression and activity, thereby influencing Rb phosphor-
ylation and cell cycle arrest, has been demonstrated to sig-
nificantly alter cell proliferation of SCC-15 [31], SCC-25
[32,33], and CAL27 cells [32] independent from p53
expression or activation. These studies suggest that modu-
lation of Rb-specific pathways by the HPV E6 and E7 genes
in these cells could be partially responsible for lowering
the barriers to G1/S cell cycle progression of these cells,
thereby increasing proliferation and cell viability in some
cases.
Our experimental results examining the changes to cell
viability, and perhaps the influence of HPV to alter the
susceptibility of these cell lines to apoptosis, suggests that
deactivation of Rb-mediated pathways, which may still be
active in these cells, may be responsible, in part, for the
observed increases in cell viability, particularly among the
CAL27 cell line. However, the differential response to
HPV strains between SCC-15 and SCC-25 cells, not only
in proliferation response but also in other cellular pheno-
types such as viability and adhesion, may be more compli-
cated than direct inhibition of Rb-specific pathways. Thus
these differential responses may involve protein binding
specificities between these two cell lines for HPV16 or
HPV18 gene products, or perhaps some other intrinsic dif-
ference or epigenetic parameter that has not yet been iden-
tified.
In fact, intrinsic differences among these cell lines have
already been noted in some previous studies [32,34]. For
example, although some of the major target genes altered
during oral carcinogenesis may be common to these cell
lines, the level of gene inactivation and mechanisms for
this gene inactivation among specific tumor suppressors
differs. For example, one study identified that p16/INK4A,
an inhibitor of cyclin CDK and G1/S cell cycle progres-
HPV mRNA was expressed in vitro only after transfectionFigure 8
HPV mRNA was expressed in vitro only after transfection. (A) RT-PCR using total RNA collected from CAL27, SCC-15 
and SCC-25 non-transfectant cells does not express HPV-mRNA (representative sample of CAL27, screened for HPV16: lane 8). 
RT-PCR confirmed the expression of HPV18-mRNA (lane 3) and HPV16-mRNA (lane 7) from all samples (CAL27 data shown). 
(B) Scanning densitometry measurement of relative endpoint RT-PCR band intensities from endogenous HPV (GH354: A, lane 5) 
were compared to HPV16, HPV18 and HPV16/18 co-transfectants, which revealed that HPV mRNA expression in all transfectants 
was roughly equivalent in all samples analyzed.
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sion, has been frequently reported as a target for inactiva-
tion in many oral cancers; however, SCC-25 cells were
found to contain a homozygous deletion of p16/INK4A,
while SCC-15 cells demonstrated hypermethylated pro-
moter deactivation of this gene, suggesting that even the
mechanisms involved in oral carcinogenesis among these
cell lines are not equivalent [34]. Further research may
lead to the identification of specific markers that will fur-
ther our understanding of tumor-specific prognosis and
treatments.
Conclusion
Although evidence suggests that high-risk HPV may
induce some percentage of oral carcinogenesis, more evi-
dence is now emerging that HPV infection may also have
the potential to significantly alter oral cancer proliferative
phenotypes and outcomes. Determining the potential of
HPV to alter phenotypic behaviors of already transformed
oral carcinomas has thus become an important step in
determining more accurately the prognosis and treatment
options for patients with oral cancer. Thus, these data,
which reveal differential responses to specific HPV strains
among oral cancers, may be the first step to identifying the
important molecular markers and pathways that could be
used to determine more effective and appropriate treat-
ment plans for oral cancer patients with concomitant oral
HPV infections. We suggest that further research in these
areas should yield additional information to help oncolo-
gists and researchers establish a rubric for generalizing the
effects and most effective treatment options for oral can-
cer patients.
Methods
Cell culture
The human OSCC cell lines used in this study, CAL27,
SCC-15, and SCC-25, were obtained from American Type
Culture Collection (ATCC: Manassas, VA). CAL27 cells
were maintained in Dulbecco's Modified Eagle's Medium
(DMEM) with 4 mM L-glutamine, adjusted to contain 3.7
g/L sodium bicarbonate and 4.5 g/L glucose from Hyclone
(Logan, UT). SCC-15 and SCC-25 cells were maintained
in a 1:1 mixture of DMEM and Ham's F12 medium with
2.5 mM L-glutamine, modified to contain 15 mM HEPES,
0.5 mM sodium pyruvate, and 1.2 g/L sodium bicarbo-
nate (ATCC), supplemented with 400 ng/ml hydrocorti-
sone from Sigma-Aldrich (St. Louis, MO). Media for all
cell lines was supplemented with 10% fetal bovine serum
(FBS), and with 1% Penicillin (10,000 units/mL)-Strepto-
mycin (10,000 Pg/mL) solution (HyClone). Cell cultures
were maintained in 75 cm2 BD Falcon tissue-culture
treated flasks (Bedford, MA) at 37°C and 5% CO2 in
humidified chambers.
Proliferation
Proliferation assays were performed of CAL27, SCC-15,
and SCC-25, transfected with HPV16, HPV18, and co-
transfected with HPV16/18, mock-transfected controls,
and un-transfected controls. Proliferation assays were per-
formed in the appropriate complete media in Corning
Costar 96-well assay plates (Corning, NY) at a concentra-
tion of 1.2 × 104 cells per well, and proliferation was
measured over three days. Cultured cells were fixed after
24 hrs (day 1), after 48 hrs (day 2), and after 72 hrs (day
3) using 50 PL of 10% buffered formalin, and were
stained with crystal violet 1% aqueous solution (Fisher
Scientific: Fair Lawn, NJ). The relative absorbance was
measured at 630 nm using a Bio-Tek ELx808 microplate
reader (Winooski, VT). Data were analyzed and graphed
using Microsoft Excel (Redmond, WA) and SPSS (Chi-
cago, IL). Three separate, independent replications of each
experiment were performed.
Viability
Prior to plating cells for adhesion and proliferation assays,
aliquots of trypsinized cells were stained using Trypan
Blue (Sigma: St. Louis, MO), and live cells were enumer-
ated by counting the number of Trypan-blue negative cells
using a VWR Scientific Counting Chamber (Plainfield, NJ)
and a Zeiss Axiovert 40 inverted microscope (Gottingen,
Germany). At each time point (day 1–3), several wells
were processed using the Trypan stain, and live cells were
enumerated using this procedure [35,36].
Adhesion
Cell adhesion assays were performed of CAL27, SCC-15,
and SCC-25, transfected with HPV16, HPV18, and co-
transfected with HPV16/18, mock-transfected controls,
and un-transfected controls. Adhesion assays were per-
formed as previously described [37,38] in uncoated Corn-
ing Costar 96-well assay plates (Corning, NY) at a
concentration of 1.2 × 105 cells per well (100 PL of 1.2 ×
106 cells/mL solution) suspended in serum-free DMEM
with no additives. Cells were allowed to attach for 30 min
at 37°C with one modification. The modified adhesion
assays used in this study eliminated the plate suspension
step, in which non-adherent cells are generally removed
by suspending the plate upside-down in a rotating tank of
PBS. Following the incubation period, the cells were fixed
using 50 PL of 10% buffered formalin and were subse-
quently stained with crystal violet 1% aqueous solution
(Fisher Scientific: Fair Lawn, NJ). The relative absorbance
was then measured at 630 nm using a Bio-Tek ELx808
microplate reader (Winooski, VT). Data were analyzed
and graphed using Microsoft Excel (Redmond, WA).
Three separate, independent replications of these assays
were performed.
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Morphology
The number and percent of spreading and non-spreading
cells were determined for each of the experimental and
control cell lines in the adhesion assays, and for each day
and condition in the proliferation assays. To accomplish
this, cells were fixed in 50 PL of 10% buffered formalin,
and were stained with crystal violet 1% aqueous solution
(Fisher Scientific: Fair Lawn, NJ). The number and percent
of spreading and non-spreading cells were then deter-
mined by visual inspection using a Zeiss Axiovert 40
inverted microscope (Gottingen, Germany) and con-
firmed with digital capture and Adobe Photoshop (San
Jose, CA) Image Analysis tools.
Transfection
CAL27, SCC-15, and SCC-25 cells were seeded in 25 cm2
BD Falcon tissue-culture treated flasks in appropriate
media as described above and allowed to achieve 70%
confluence. Cells were then transiently transfected by add-
ing 1 Pg/mL of the full-length HPV type 16, cloned into
the pBluescript SK-vector (ATCC #45113) and/or the HPV
type 18, cloned into the pBR322 vector (ATCC #45152).
These cell lines were also co-transfected with 1 Pg/mL of
HPV16 and 1 Pg/mL of HPV18. The transfections were
performed using the Stratagene Mammalian Transfection
Kit (La Jolla, CA) according to the manufacturer's recom-
mended protocol for CaPO4 transfection. Mock transfect-
ants (mTF) of these three cell lines were also established
by performing the same transfection protocol, but with-
out using virus.
RT-PCR
RNA was isolated from 1.5 × 107 cells of each of the exper-
imental and control cell lines, using ABgene Total RNA
Isolation Reagent (Epsom, Surrey, UK) and the procedure
recommended by the manufacturer. RT-PCR was per-
formed with the ABgene Reverse-iT One-Step RT-PCR Kit
(ReadyMix Version) and a Mastercycler gradient thermo-
cycler (Eppendorf: Hamburg, Germany) using the follow-
ing primers synthesized by SeqWright (Houston, TX):
HPV18 forward primer, ATGGCGCGCTTTGAGGATCC;
HPV18 reverse primer, GCATGCGGTATACTGTCTCT;
HPV16 forward primer, ATGTTTCAGGACCCACAGGA;
HPV16 reverse primer, CCTCACGTCGCAGTAACTGT.
One Pg of template RNA was used for each reaction. The
reverse transcription step ran for 30 min at 47°C, fol-
lowed by denaturation for 2 min at 94°C. Thirty-five
amplification cycles were run, consisting of 20 sec dena-
turation at 94°C, 30 sec of annealing at 58°C, and 6.5
min of extension at 72°C. Final extension was run for 5
min at 72°C. Reaction products were separated by gel
electrophoresis using Reliant 4% agarose gels (Cambrex:
Rockland, ME). Bands were visualized by UV illumination
of EtBr-stained gels and captured using a Kodak Gel Logic
100 Imaging System and 1D Image Analysis Software
(Eastman Kodak: Rochester, NY).
Statistics
The differences between treatments were measured using
a t distribution, D = .05. All samples were analyzed using
two-tailed t tests as departure from normality can make
more of a difference in a one-tailed than in a two-tailed t
test. As long as the sample size is even moderate (>20) for
each group, quite severe departures from normality make
little practical difference in the conclusions reached from
these analyses [39]. To confirm the effects observed from
these experiments, further analysis of the data was facili-
tated with ANOVA using SPSS (Chicago, IL). Significance
for ANOVA was 0.05.
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